UBS Group
AURA icon

UBS Group’s Aura Biosciences AURA Stock Holding History

UBS Group’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$795K Sell
118,904
-52,735
-31% -$303K ﹤0.01% 5730
2025
Q4 		$935K Sell
171,639
-725,172
-81% -$4.31M ﹤0.01% 5636
2025
Q3 		$5.54M Buy
896,811
+5,783
+0.6% +$37.8K ﹤0.01% 3928
2025
Q2 		$5.58M Buy
891,028
+137,870
+18% +$806K ﹤0.01% 3762
2025
Q1 		$4.41M Buy
753,158
+65,836
+10% +$498K ﹤0.01% 3914
2024
Q4 		$5.65M Buy
687,322
+665,336
+3,026% +$6.26M ﹤0.01% 3692
2024
Q3 		$196K Buy
21,986
+7,721
+54% +$66.2K ﹤0.01% 5890
2024
Q2 		$108K Sell
14,265
-22,381
-61% -$164K ﹤0.01% 6123
2024
Q1 		$288K Buy
36,646
+5,584
+18% +$46.3K ﹤0.01% 5600
2023
Q4 		$275K Buy
31,062
+30,337
+4,184% +$257K ﹤0.01% 5563
2023
Q3 		$6.5K Buy
+725
New +$7.8K ﹤0.01% 7296
2023
Q2 		– Sell
-545
Closed -$5.06K – 8895
2023
Q1 		$5.06K Sell
545
-559
-51% -$5.81K ﹤0.01% 8090
2022
Q4 		$11.6K Sell
1,104
-11,163
-91% -$142K ﹤0.01% 8381
2022
Q3 		$222K Sell
12,267
-4,053
-25% -$61.3K ﹤0.01% 4996
2022
Q2 		$231K Buy
16,320
+15,566
+2,064% +$258K ﹤0.01% 4798
2022
Q1 		$17K Sell
754
-1,893
-72% -$36.1K ﹤0.01% 7633
2021
Q4 		$45K Buy
+2,647
New +$47.3K ﹤0.01% 6995

Other funds holding AURA

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

UBS Group's AURA Position: Q1 2026 in Review

UBS Group reduced its Aura Biosciences (AURA) stake by 31% in Q1 2026, selling an estimated $303K and leaving 118,904 shares worth $795K. The position accounts for ﹤0.01% of the portfolio, ranked #5730.

UBS Group first reported a position in AURA in Q4 2021 and has held it in 17 quarters since. The position peaked at $5.65M in Q4 2024. 126 funds tracked by Wall St. Rank hold AURA as of Q1 2026.

  • UBS Group held 118,904 shares of Aura Biosciences worth $795K as of Q1 2026.
  • UBS Group sold 52,735 Aura Biosciences shares in Q1 2026, an estimated $303K.
  • Aura Biosciences made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5730 holding.
  • UBS Group first reported a position in Aura Biosciences in Q4 2021 and has held it in 17 quarters since.
  • UBS Group's Aura Biosciences position peaked at $5.65M in Q4 2024.
  • 126 funds tracked by Wall St. Rank held Aura Biosciences as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.